BXP vs DMAC · rev $3.48B vs $157.4M cap
Boston Properties Inc (BXP) versus DiaMedica Therapeutics Inc (DMAC) — a side-by-side from cached financials, not a winner call.
Boston Properties Inc (BXP) is a reit - office company listed on US.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Latest reported BXP revenue for 2025-12-31 was $3.48B. Net income was $276.8M. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BXP currently screens at market cap $12.12B.
DMAC does not have a complete income-statement cache yet.
BXP currently screens at market cap $12.12B. DMAC currently screens at market cap $157.4M.
Not investment advice. Open the BXP and DMAC stock pages for the full models.
Not investment advice.